23 Jul 2021
Posted in Pharma
12-month total prevalent cases of migraine to reach 73.7 million by 2030 in the 7MM, says GlobalData
The 12-month total prevalent cases of migraine in the seven major markets (*7MM) are expected to increase from 72.7 million cases in 2020 to 73.7 million cases in 2030, at an annual growth rate (AGR) of 0.13%, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, ‘Migraine – Epidemiology Forecast to 2030’, reveals that in 2030, the US will have the highest number of 12-month total prevalent cases of migraine in the 7MM at 42.6 million cases, whereas Spain will have the lowest number of cases with nearly 3.9 million.
Young adults up to those aged 50 accounted for more than 72% of the 12-month total prevalent cases of migraine in the 7MM, while those aged 70 years and older accounted for less than 10%. Moreover, migraine has consistently been described in studies to be more common in women compared to men. In the 7MM, the 12-month total prevalent cases of episodic migraine were predominantly based on frequency. In terms of type, migraine without aura was the most common type for migraine in the 7MM.
Antara Bhattacharya, MPH, Senior Epidemiologist at GlobalData, comments: “A higher burden of migraine in the productive age groups and disabling symptoms both substantially increase the economic burden of migraine. Despite this, the disease remains highly undiagnosed and undertreated. Therefore, more country-specific epidemiological studies are needed to elucidate the prevalence proportions in the adult population.”
“While there is no cure for migraine, early diagnosis, as well as symptomatic and preventive treatments, can reduce the severity of attacks. Consequently, better knowledge of the aetiology of migraine will lead to early diagnosis and disease prevention.”
*7MM: US, France, Germany, Italy, Spain, UK, and Japan